InvestorsHub Logo
Post# of 253168
Next 10
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

Re: jq1234 post# 228392

Thursday, 01/23/2020 7:38:04 PM

Thursday, January 23, 2020 7:38:04 PM

Post# of 253168

NKTR—I never heard WL in any previous CC…he seemed better than others.

He’s well qualified for the job:

https://www.nektar.com/company/our-leadership

Wei Lin, M.D., joined Nektar in November 2018 as Senior Vice President of Clinical Development and Head of Nektar’s Oncology Programs... Prior to joining Nektar, Dr. Lin served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer at Genentech. During his seven years at Genentech, he held several senior leadership positions of increasing responsibility including Global Clinical Leader of Cancer Immunotherapy in lung and head and neck cancer, where he led a team of 20 medical directors and clinical scientists and directed clinical development strategy for cancer immunotherapy in lung cancer and executed registration trials in lung cancer and head and neck cancer including the successful readouts of five Phase 3 trials in first-line lung cancer and regulatory filing of three of these trials.

…Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals. Dr. Lin received a B.A. in physics from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center.

None of this guarantees that bempeg will work out, of course.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.